Adverse events290

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

141 to 160 of 290

Type	Event	Organ system	Group	Affected	At risk
other	Headache	Nervous system disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	0	30
other	Headache	Nervous system disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	1	30
other	Headache	Nervous system disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	2	30
other	Headache	Nervous system disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	21	1,162
other	Headache	Nervous system disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	7	1,161
serious	Atrial septal defect	Congenital, familial and genetic disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	0	30
serious	Atrial septal defect	Congenital, familial and genetic disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	0	30
serious	Atrial septal defect	Congenital, familial and genetic disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	0	30
serious	Atrial septal defect	Congenital, familial and genetic disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	1	1,162
serious	Atrial septal defect	Congenital, familial and genetic disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	0	1,161
serious	Congenital hydronephrosis	Congenital, familial and genetic disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	0	30
serious	Congenital hydronephrosis	Congenital, familial and genetic disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	0	30
serious	Congenital hydronephrosis	Congenital, familial and genetic disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	0	30
serious	Congenital hydronephrosis	Congenital, familial and genetic disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	1	1,162
serious	Congenital hydronephrosis	Congenital, familial and genetic disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	0	1,161
serious	Gastritis	Gastrointestinal disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	0	30
serious	Gastritis	Gastrointestinal disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	0	30
serious	Gastritis	Gastrointestinal disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	0	30
serious	Gastritis	Gastrointestinal disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	1	1,162
serious	Gastritis	Gastrointestinal disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	0	1,161

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03110770/events?page=8

API reference For AI assistants